Amubarvimab
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2].
Product Specifications
CAS Number
2509447-07-6
Product Name Alternative
BRII-196
UNSPSC
12352203
Target
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/amubarvimab.html
Purity
95.00
Solubility
H2O
Smiles
[Amubarvimab]
Molecular Weight
(143.84 kDa)
References & Citations
[1]Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. |[2]Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82 (12) :1327-1331.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6378216-01 0.1 mL
FBP2 (Fructose-1,6-bisphosphatase isozyme 2, FBPase 2, D-fructose-1,6-bisphosphate 1-phosphohydrolase 2, MGC142192) (MaxLight 750)
Sign In for Pricing
View Details MBS6378216-02 5x 0.1 mL
FBP2 (Fructose-1,6-bisphosphatase isozyme 2, FBPase 2, D-fructose-1,6-bisphosphate 1-phosphohydrolase 2, MGC142192) (MaxLight 750)
Sign In for Pricing
View Details 
